[1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33.
|
[2] |
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention[J]. Clin Chest Med, 2011, 32(4): 605-644.
|
[3] |
Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update[J]. J Clin Oncol, 2020, 38(14): 1608-1632.
|
[4] |
Kris M, Gaspar L, Chaft J, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I toⅢA completely resected non-small-cell lung cancers: American society of clinical oncology/cancer care ontario clinical practice guideline update[J]. J Clin Oncol, 2017, 35(25): 2960-2974.
|
[5] |
Daly M, Singh N, Ismaila N, et al. Management of stage Ⅲ non-small-cell lung cancer: ASCO guideline[J]. J Clin Oncol, 2022, 40(12): 1356-1384.
|
[6] |
Osataphan N, Phrommintikul A, Chattipakorn S, et al. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions[J]. J Cell Mol Med, 2020, 24(12): 6534-6557.
|
[7] |
Patra J, Das G, Fraceto L, et al. Nano based drug delivery systems: recent developments and future prospects[J]. J Nanobiotechnology, 2018, 16(1): 71.
|
[8] |
Hong G, Diao S, Antaris A, et al. Carbon nanomaterials for biological imaging and nanomedicinal therapy[J]. Chem Rev, 2015, 115(19): 10816-10906.
|
[9] |
Zeng Q, Shao D, He X, et al. Carbon dots as a trackable drug delivery carrier for localized cancer therapy in vivo[J]. J Mater Chem B, 2016, 4(30): 5119-5126.
|
[10] |
Tang J, Kong B, Wu H, et al. Carbon nanodots featuring efficient FRET for real-time monitoring of drug delivery and two-photon imaging[J]. Adv Mater, 2013, 25(45): 6569-6574.
|
[11] |
Karthik S, Saha B, Ghosh S, et al. Photoresponsive quinoline tethered fluorescent carbon dots for regulated anticancer drug delivery[J]. Chem Commun (Camb), 2013, 49(89): 10471-10473.
|
[12] |
Baker S, Baker G. Luminescent carbon nanodots: emergent nanolights[J]. Angew Chem Int Ed Engl, 2010, 49(38): 6726-6744.
|
[13] |
Liu C, Zhang P, Zhai X, et al. Nano-carrier for gene delivery and bioimaging based on carbon dots with PEI-passivation enhanced fluorescence[J]. Biomaterials, 2012, 33(13): 3604-3613.
|
[14] |
Hou J, Yan J, Zhao Q, et al. A novel one-pot route for large-scale preparation of highly photoluminescent carbon quantum dots powders[J]. Nanoscale, 2013, 5(20): 9558-9561.
|
[15] |
Yang L, Wang Z, Wang J, et al. Doxorubicin conjugated functionalizable carbon dots for nucleus targeted delivery and enhanced therapeutic efficacy[J]. Nanoscale, 2016, 8(12): 6801-6809.
|
[16] |
Yu H, Lv X, Wu L, et al. Doxorubicin-loaded fluorescent carbon dots with PEI passivation as a drug delivery system for cancer therapy[J]. Nanoscale, 2020, 12(33): 17222-17237.
|
[17] |
Xu J, Sahu S, Cao L, et al. Carbon nanoparticles as chromophores for photon harvesting and photoconversion[J]. Chemphyschem, 2011, 12(18): 3604-3608.
|
[18] |
Lages E, Fernandes R, Silva J, et al. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity[J]. Biomed Pharmacother, 2020, 132: 110876.
|
[19] |
Sohail M, Sun Z, Li Y, et al. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy[J]. Expert Rev Anticancer Ther, 2021, 21(12): 1385-1398.
|